Endocrinology

Two-year CAHtalyst data show crinecerfont sustains androgen reduction and lowers glucocorticoid doses in children with congenital adrenal hyperplasia.

FDA expands teplizumab (Tzeld) use to children as young as 1 year with stage 2 type 1 diabetes, aiming to delay progression to clinical disease.

Updated guidance outlines triglyceride thresholds that distinguish ASCVD vs pancreatitis risk and inform targeted management strategies in children.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

FDA okays once-weekly navepegritide for children with achondroplasia, boosting growth with strong trial data; rollout expected early Q2 2026.

With the priority review, the Prescription Drug User Fee Act date is set for April 29, 2026, for potential approval in this younger indication.

Ferric maltol is now an FDA-approved oral iron therapy for both adults and adolescents with iron deficiency, aged 10 years and older.

Experts discussed how the 3-stage model reframed type 1 diabetes as a condition that could be detected through earlier screening.

This introductory Special Report episode outlines how advances in staging and early detection are reshaping pediatric approaches to type 1 diabetes.

Jonathan Flyer, MD, discusses how the LEAD Pediatric Initiative is addressing persistently low rates of universal pediatric lipid screening.

See the full case of our most recent puzzler quiz, and view the correct diagnosis of this slender teen with a growing abdomen and shrinking height.

Jonathan Flyer, MD, emphasizes that early detection of FH through guideline-recommended universal screening can be lifesaving and supports broader family identification.

Jonathan Flyer, MD, highlights strategies to improve universal pediatric lipid screening and early detection of familial hypercholesterolemia in children.

Explore groundbreaking therapies for type 1 diabetes that aim to delay onset, preserve β-cell function, and restore insulin independence.

From another potential treatment for pediatric atopic dermatitis, to STI therapy for uncomplicated urogenital gonorrhea, take a look ahead at key PDUFA dates in Q4.

The Phase 3 SURPASS-PEDS trial found tirzepatide improved glycemic control and weight outcomes in youth-onset type 2 diabetes, with benefits lasting one year.

Michael Haller, MD, tell providers they shouldn't be surprised if more children with T1D use inhaled insulin.

Michael Haller, MD, discusses inhaled insulin’s safety, off-label use, and future role in easing type 1 diabetes management for children.

Richard Auchus, MD, PhD, discusses how crinecerfont is improving CAH care and easing the transition from pediatric to adult management.

Manufacturer MannKind has submitted a supplemental Biologics Application to the FDA for its inhaled insulin Afrezza.

The FDA accepted Eton Pharmaceuticals' NDA for ET-600 for pediatric arginine vasopressin deficiency, with a target action date in February of 2026.

The combination therapy yielded boosted treatment benefits of navepegritide, including improvement in mean ACH Z-score and mean annualized growth.

With the new drug application accepted with priority review, the FDA has assigned a date of November 30, 2025, to complete its review for potential approval.

The decision makes hydrocortisone oral solution (Khindivi; Eton Pharmaceuticals) the only FDA-approved oral formulation of hydrocortisone.